HANSOH PHARMA Receives NMPA Acceptance for New Drug Application of HS-10568 Injection

Stock News06-10 18:44

HANSOH PHARMA (03692) has announced that the New Drug Application for its innovative product, HS-10568 injection, has been accepted for review by China's National Medical Products Administration.

The application, submitted on June 9, 2026, seeks marketing authorization for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease who are undergoing hemodialysis.

HS-10568, also known under the partner code SHR6508, functions as a calcium-sensing receptor allosteric modulator. Its mechanism of action involves increasing the receptor's sensitivity to extracellular calcium, which subsequently leads to a reduction in the secretion of parathyroid hormone.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141642657?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141642657","market":"other","top_or_hot":-1,"title":"HANSOH PHARMA Receives NMPA Acceptance for New Drug Application of HS-10568 Injection","media":"Stock News","content":"<p><b>HANSOH PHARMA</b> (<b>03692</b>) has announced that the New Drug Application for its innovative product, HS-10568 injection, has been accepted for review by China's National Medical Products Administration.<br><br>The application, submitted on June 9, 2026, seeks marketing authorization for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease who are undergoing hemodialysis.<br><br>HS-10568, also known under the partner code SHR6508, functions as a calcium-sensing receptor allosteric modulator. Its mechanism of action involves increasing the receptor's sensitivity to extracellular calcium, which subsequently leads to a reduction in the secretion of parathyroid hormone.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANSOH PHARMA Receives NMPA Acceptance for New Drug Application of HS-10568 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANSOH PHARMA Receives NMPA Acceptance for New Drug Application of HS-10568 Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-10 18:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>HANSOH PHARMA</b> (<b>03692</b>) has announced that the New Drug Application for its innovative product, HS-10568 injection, has been accepted for review by China's National Medical Products Administration.<br><br>The application, submitted on June 9, 2026, seeks marketing authorization for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease who are undergoing hemodialysis.<br><br>HS-10568, also known under the partner code SHR6508, functions as a calcium-sensing receptor allosteric modulator. Its mechanism of action involves increasing the receptor's sensitivity to extracellular calcium, which subsequently leads to a reduction in the secretion of parathyroid hormone.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1141642657","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141642657","pubTimestamp":1781088290,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HANSOH PHARMA (03692) has announced that the New Drug Application for its innovative product, HS-10568 injection, has been accepted for review by China's National Medical Products Administration.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药","IPOS":"Renaissance International IPO ETF","BK1583":"高瓴概念","BK1589":"北水核心资产","BK1191":"制药"},"translate_title":"翰森制药HS-10568注射液新药申请获NMPA受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"03692":1},"content_text":"HANSOH PHARMA (03692) has announced that the New Drug Application for its innovative product, HS-10568 injection, has been accepted for review by China's National Medical Products Administration.The application, submitted on June 9, 2026, seeks marketing authorization for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease who are undergoing hemodialysis.HS-10568, also known under the partner code SHR6508, functions as a calcium-sensing receptor allosteric modulator. Its mechanism of action involves increasing the receptor's sensitivity to extracellular calcium, which subsequently leads to a reduction in the secretion of parathyroid hormone.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141642657","isCrawlerRequest":true}